A Phase 2 Open-label Multicenter Study of an Immunotherapeutic Treatment DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab in Subjects with Selected Advanced and Recurrent Solid Tumours.

Go Back to All Clinical Trials

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Other Inclusion Criteria:

1) Patients with advanced or metastatic solid tumours who have disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, are intolerant to treatment, or refuse standard treatment. There is no limit to the number of prior treatment regimens. 2) Checkpoint inhibitor naïve or prior exposure to anti–CTLA-4, anti–PD-1/L1 mAb is allowed. 3) Radiologic and/or biochemical evidence of disease progression.

1) Chemotherapy or immunotherapy treatment within 28 days. 2) Receipt of prior radiotherapy within 2 weeks of start of study treatment. 3) Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor (e.g., CTLA-4, OX40, CD137) where subject was discontinued from that treatment due to a Grade 3 or higher immune-related toxicity (irAE). 4) Prior receipt of investigational immune therapy (other than those above-mentioned) must be discussed with the medical monitor to determine eligibility.